• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br In conclusion these hypothesis generating findings support further consideration


    In conclusion, these hypothesis-generating findings support further consideration of adjuvant regimens that include the delivery of CT be-fore RT. For women with locally advanced Type 1 EC, treatment with multi-agent CT before RT (or potentially employing a sandwich ap-proach) may optimize control of both locoregional and distant disease, ultimately leading to longer PFS and OS. The findings presented here support the consideration of this Cycloheximide regimen in the design Cycloheximide of future pro-spective trials.
    Supplementary data to this article can be found online at https://doi.
    We acknowledge the NCDB for collecting the data used in these anal-yses. The NCDB and the participating hospitals are the source of the data. The NCDB has not verified and are not responsible for the statisti-cal validity of the data analysis or conclusions.
    Conflict of interest statement
    Dr. Matei reports personal fees from Astra Zeneca, Genentech/Roche, Tesaro, Astex, Clovis, and the European commission that are outside the submitted work. All other authors report no conflicts of interest.
    Author contributions
    Conceptualization: Goodman, Seagle, Strauss. Formal Analysis and
    Methodology: Goodman, Strauss, Hatoum, Seagle. Writing – Original
    Draft: Goodman, Hatoum; Writing – Review and Editing: Goodman,
    Hatoum, Seagle, Barber, Matei, Strauss. Project Administration: Hatoum,
    Donnelly, Barber, Matei, Shahabi, Strauss. Supervision: Strauss, Shahabi.
    [1] S.M. de Boer, M.E. Powell, L. Mileshkin, et al., Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial, Lancet Oncol. 19 (3) (2018) 295–309. [2] D. Matei, V.L. Filiaci, M. Randall, et al., A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma, J. Clin. Oncol. 35 (15_suppl) (2017) 5505. [3] K.Y. Bilimoria, A.K. Stewart, D.P. Winchester, C.Y. Ko, The National Cancer Data Base: a Sporulation powerful initiative to improve cancer care in the United States, Ann. Surg. Oncol. 15 (3) (2008) 683–690.
    [13] MatchIt, Nonparametric Preprocessing for Parametric Causal Inference, computer program 2011. [14] T.M. Therneau, A Package for Survival Analysis in S. Version 2.38, 2015. [15] Team RC (Ed.), R: A Language and Environment for Statistical Computing, R Foun-dation for Statistical Computing, Vienna, Austria, 2016. [16] R. Maggi, A. Lissoni, F. Spina, et al., Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial, Br. J. Cancer 95 (3) (2006) 266–271.
    [17] N. Susumu, S. Sagae, Y. Udagawa, et al., Randomized phase III trial of pelvic radio-therapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study, Gynecol. Oncol. 108 (1) (2008) 226–233.
    [18] M.E. Randall, V.L. Filiaci, H. Muss, et al., Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study, J. Clin. Oncol. 24 (1) (2006) 36–44.
    [19] H. Gao, Z. Zhang, Sequential chemotherapy and radiotherapy in the sandwich method for advanced endometrial cancer: a meta-analysis, Medicine (Baltimore) 94 (16) (2015) e672.
    [20] M. Glasgow, R.I. Vogel, J. Burgart, P. Argenta, K. Dusenbery, M.A. Geller, Long term follow-up of a phase II trial of multimodal therapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer, Gynecol. Oncol. Res. Pract. 3 (2016) 6.